SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high December and fourth-quarter 2025 vehicle deliveries, meeting the high end of its guidance and nearing one million cumulative vehicles overall. This strong performance, coupled with China's extended EV purchase tax benefits favoring battery-swapping models, has ignited community discussions about potential Q4 profitability and a bright 2026 outlook for the multi-brand EV maker. Many investors are optimistic, comparing NIO's sales favorably against peers and anticipating significant upside despite recent price volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community actively champions the "OG meme" narrative of Rage Comics, viewing it as the foundational "meme reset." This dedicated base is passionately building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and widespread recognition as they aim to lead the next major meme coin cycle.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending due to its recent partnership with Google Cloud for the Agentic Interop Summit, signaling increased recognition and strategic positioning within the AI ecosystem. The community is also reacting to Ocean Protocol's departure from the ASI Alliance, which has led to a significant FET token burn, viewed by many as a deflationary catalyst. Despite past volatility, investors are actively discussing Fetch.ai's potential for real-world AI agent adoption and its perceived undervaluation within the broader AI crypto sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is actively discussed after announcing plans to distribute new digital tokens to shareholders via Crypto.com. This move is generating polarized community reactions, with some investors seeing it as a potential short squeeze catalyst and shareholder reward, while others view the non-transferable tokens as a "worthless" incentive or a "pump and dump" scheme. The debate reflects ongoing concerns about the company's financial performance and future strategy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending significantly following the FDA's Complete Response Letter to competitor Corcept Therapeutics for its Cushing's syndrome treatment. This outcome is widely viewed by the community and analysts as a "massive tailwind" for Xeris's Recorlev, strengthening its market position in a growing multi-billion dollar sector. Investors are actively discussing this enhanced competitive moat and the promising future of its XP-8121 pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TriSalus Life Sciences Inc. (TLSI) shares were in the spotlight on Thursday morning after the company’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.trisaluslifesci.com/news-releases/news-release-details/trisalus-life-sciences-reports-q4-and-full-year-2024-financial">fourth-quarter</a> loss exceeded Wall Street projections, but revenue topped expectations.TriSalus reported a 44% jump in its fourth-quarter (Q4) revenue to $8.3 million, higher than an analyst estimate of $8.25 million, according to FinChat data.The company’s loss per share narrowed to $0.4, compared to $1.57 in the same quarter a year ago, but it was wider than the estimated loss of $0.32.TriSalus reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. &nbsp;The oncology-focused medical technology company also said that it expects to be earnings before interest, tax, depreciation, and amortization (EBITDA) positive this year and achieve positive cash flow by the second half, extending its total cash runaway beyond this year.The company ended 2024 with $8.5 million in cash and cash equivalents.Operating expenses are also expected to reduce over 20% owing to reductions in research and development costs.On Stocktwits, retail sentiment continued to trend in the ‘extremely bearish’ territory while message volume jumped from ‘low’ to ‘high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_11_02_29_AM_png_72bc5e484f.webp" alt="TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="151"><figcaption>TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company’s guidance.<stembedurl>https://stocktwits.com/FE123/message/609391420</stembedurl>Another highlighted the company’s growth in revenue.<stembedurl>https://stocktwits.com/FE123/message/609361644</stembedurl><a href="https://stocktwits.com/symbol/TLSI">TLSI shares</a> gained by over 12% this year but are down by over 40% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-sells-jamaican-assets-to-excelerate-energy/chJ2EtuRbE4">New Fortress Energy Sells Jamaican Assets, Operations To Excelerate Energy For $1.06B: Stock Tumbles But Retail Cheers The Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 

Current Price	$29.79
Prev Close	$29.89
Open	$29.84
Dividend Yield	N/A
50-Day Moving Average	$29.03
Beta	N/A
Avg. Volume	27,587.00
PE Ratio	N/A

52-Week High	$32.21
52-Week Low	$20.99
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IMFL
Invesco International Developed Dynamic Multifactor ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IMFL News

IMFLInvesco International Developed Dynamic Multifactor ETF